 Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Melatonin is an important hormone that regulates circadian rhythm. Melatonin also demonstrates antioxidant, immunomodulating, and anti-tumor activity. In this top-performing research paper published by Alko Target in 2020, researchers conducted a retrospective study of 955 prostate cancer patients who received combined hormone radiation treatment between 2000 and 2019. The researchers used comprehensive statistical analysis to measure the overall survival rate of prostate cancer patients who were treated with melatonin. Read this study and more peer-reviewed oncology-focused research published by AlkoTarget at AlkoTarget.com.